The Supreme Court declined to review a petition filed by Novartis’ Sandoz unit that challenged two of Amgen’s patents on its blockbuster rheumatoid arthritis drug, Enbrel, meaning there won’t be a ...

In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it. By Rebecca Robbins With a sticker price ...

Getting your Trinity Audio player ready... A Colorado board voted to move forward with setting a price ceiling on the arthritis drug Enbrel on Friday, a first-in-the-nation step that raises questions ...

A state board in Colorado is working to make history by becoming the first in the country to cap the price of a drug it deems unaffordable. Amid an aggressive industry lobbying campaign, Colorado ...